Protagonist closes tranche in $18M round; Teva pays a $15M milestone;

@FierceBiotech: Party time at Array as Novartis bows out of PhIII binimetinib cancer program. Report | Follow @FierceBiotech

@JohnCFierce: College students with big ideas can shoot for some seed money from Xfund. Harvard-based--$100M. More from the WSJ | Follow @JohnCFierce

@DamianFierce: Blincyto, which sounds like it's related to the cells of blintzes, is the name of Amgen's new cancer drug. More | Follow @DamianFierce

> Milpitas, CA-based Protagonist Therapeutics has closed on the second tranche of its $18 million B round. The biotech is using the money to advance toward the clinic with PTG-100, an alpha-4-beta-7 integrin specific antagonist peptide for inflammatory bowel disease. Release

> CTI BioPharma received a $15 million milestone payment from Teva ($TEVA) related to the achievement of sales milestones for Trisenox (arsenic trioxide). Release

Medical Device News

@FierceMedDev: ICYMI: Illumina and Sequenom lay ongoing prenatal diagnostic patent feud to rest. Article | Follow @FierceMedDev

@EmilyWFierce: Britain's BTG scoops up pulmonology outfit PneumRx for up to $475M. Story | Follow @EmilyWFierce

> Zimmer makes a divestiture proposal to appease EU regulators in Biomet acquisition. Item

> Hospital requires use of wireless, wearable sensors to prevent bedsores. News

> HeartFlow's noninvasive test for coronary artery disease cleared by FDA. More

Pharma News

@FiercePharma: Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. FierceVaccines article | Follow @FiercePharma

@EricPFierce: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. News | Follow @EricPFierce

@CarlyHFierce: Universal flu vaccine developer BiondVax mulling IPO. Globes | Follow @CarlyHFierce

> Incyte's Jakafi gets a boost with FDA nod for bone marrow disease. More

> Ranbaxy now faces product bans in Europe. Story

> Bayer and J&J push back against consolidation of Xarelto suits. News

Vaccines News

> Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. Article

> Universal flu vax developer BiondVax mulling IPO: Globes. Item

> GSK, NIH gear up for Ebola vaccine trial expansion after success in PhI. Report

> Merck, NewLink Ebola vaccine trial shows no serious side effects so far. Story

> Novartis' Fluad off the hook in Italy following 19 deaths. Article

Pharma Manufacturing News

> EMA clears Novartis Fluad in deaths in Italy. Item

> Johnson Matthey buys former Glaxo facility in Scotland. More

> Strides Arcolab begins construction of $60M Malaysia facility. Report

> Some Indian drugmakers routinely toss out bad test results: Bloomberg. Story

> Germany, EU, join U.S. in banning India-made Ranbaxy products. Article

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.